Cargando…

Predictive Modeling Identifies Total Bleeds at 12-Weeks Postswitch to N8-GP Prophylaxis as a Predictor of Treatment Response

Background Predicting annualized bleeding rate (ABR) during factor VIII (FVIII) prophylaxis for severe hemophilia A (SHA) is important for long-term outcomes. This study used supervised machine learning-based predictive modeling to identify predictors of long-term ABR during prophylaxis with an ext...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chowdary, Pratima, Hampton, Kingsley, Jiménez-Yuste, Victor, Young, Guy, Benchikh el Fegoun, Soraya, Cooper, Aidan, Scalfaro, Erik, Tiede, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251711/ https://www.ncbi.nlm.nih.gov/pubmed/34865209 http://dx.doi.org/10.1055/s-0041-1739514

Ejemplares similares

Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2
por: Llibre, Josep M., et al.
Publicado: (2022)

Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A
por: Chowdary, Pratima, et al.
Publicado: (2019)

Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model
por: Tiede, Andreas, et al.
Publicado: (2020)

Double J stent reduces the efficacy of extracorporeal shock wave lithotripsy in the treatment of lumbar ureteral stones
por: Pettenati, Caroline, et al.
Publicado: (2013)

HAEMOcare: The First International Epidemiological Study Measuring Burden of Hemophilia in Developing Countries
por: Gupta, Naresh, et al.
Publicado: (2019)

Real-World Early Treatment with Room Temperature–Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc Analyses
por: Demartis, Francesco, et al.
Publicado: (2017)

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
por: Shapiro, Amy D., et al.
Publicado: (2022)

Asymptomatic Joint Bleeding and Joint Health in Hemophilia: A Review of Variables, Methods, and Biomarkers
por: Gooding, Richard, et al.
Publicado: (2021)

Efficacy of EHL N9-GP for on-demand treatment of bleeding episodes in hemophilia B: analysis of pivotal trial data
por: Escobar, Miguel A, et al.
Publicado: (2019)

Three-Dimensional Navigation (O-arm) for Minimally Invasive Shelf Acetabuloplasty
por: Severyns, Mathieu, et al.
Publicado: (2020)

Mechanisms regulating IgA class-specific immunoglobulin production in murine gut-associated lymphoid tissues. II. Terminal differentiation of postswitch sIgA-bearing Peyer's patch B cells
Publicado: (1983)

Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries
por: Bensadok, Meriem, et al.
Publicado: (2017)

Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data
por: Eichler, Hermann, et al.
Publicado: (2018)

Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)
por: Klamroth, Robert, et al.
Publicado: (2021)

Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials
por: Tosetto, Alberto, et al.
Publicado: (2020)

Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab
por: Chowdary, Pratima
Publicado: (2018)

COVID‐19 coagulopathy – what should we treat?
por: Chowdary, Pratima
Publicado: (2022)

Variceal Bleeding Prophylaxis: Variceal Banding or Propranolol
por: Van Stiegmann, Gregory
Publicado: (2000)

Primary and secondary prophylaxis of gastric variceal bleeding
por: Kochar, Rajan, et al.
Publicado: (2010)

Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis
por: Pabinger, Ingrid, et al.
Publicado: (2017)

Safety of renal biopsy bleeding prophylaxis with desmopressin
por: Barrios, R. Haridian Sosa, et al.
Publicado: (2021)

Bleeding risk assessment for venous thromboembolism prophylaxis
por: Chindamo, Maria Chiara, et al.
Publicado: (2021)

Compliance with Primary Malaria Chemoprophylaxis: Is Weekly Prophylaxis Better Than Daily Prophylaxis?
por: Rodrigo, Chaturaka, et al.
Publicado: (2020)

Role of band ligation for secondary prophylaxis of variceal bleeding
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2018)

Basic knowledge among GP trainees regarding HIV pre- and post-exposition-prophylaxis
por: Flössner, Christian, et al.
Publicado: (2021)

Adherence to prophylaxis and bleeding outcome: A multicenter Nigerian study
por: Nwagha, Theresa Ukamaka, et al.
Publicado: (2023)

Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis
por: Pipe, Steven W., et al.
Publicado: (2023)

Serious bleeds in pediatric persons with hemophilia A on emicizumab prophylaxis
por: Garcia, Jessica, et al.
Publicado: (2023)

Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding
por: Higuera-de-la-Tijera, Fátima, et al.
Publicado: (2018)

Retrospective Review of a Prothrombin Complex Concentrate (Beriplex P/N) for the Management of Perioperative Bleeding Unrelated to Oral Anticoagulation
por: Chowdary, Pratima, et al.
Publicado: (2018)

Once‐weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8‐GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial)
por: Curry, Nicola, et al.
Publicado: (2019)

Upper gastrointestinal bleeding prophylaxis: gap between guidelines and clinical practice
por: Orlandi, DM, et al.
Publicado: (2007)

Bleeding prevalence in COVID-19 patients receiving intensive antithrombotic prophylaxis
por: Kessler, Chiara, et al.
Publicado: (2020)

Major bleeding events in octagenarians associated with drug interactions between dabigatran and P-gp inhibitors
por: Bernier, Marjorie, et al.
Publicado: (2019)

Single Chain Antibodies Against gp55 of Human Cytomegalovirus (HCMV) for Prophylaxis and Treatment of HCMV Infections
por: Moazen, Bahareh, et al.
Publicado: (2016)

Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: post hoc subanalysis of the randomized, phase 3 PROPEL study
por: Escuriola-Ettingshausen, Carmen, et al.
Publicado: (2023)

Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study
por: Dover, Saunya, et al.
Publicado: (2020)

Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS
por: Lalezari, S, et al.
Publicado: (2014)

Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII
por: Jonsson, Fredrik, et al.
Publicado: (2021)

Phytophotodermatose aux algues marines de localisation inhabituelle
por: Chakir, Karima, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1uob3v01mpdngd2g2j83eeqr87